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Abstract: 
Background: Human neural stem cell implantation may offer improved recovery from stroke. We 
investigated the feasibility of intracerebral implantation of the allogeneic human neural stem cell 
line CTX0E03 in the subacute – chronic recovery phase of stroke and potential measures of 
therapeutic response in a multicentre study. 
Methods: We undertook a prospective, multicentre, single-arm, open label study in adults aged >40 
years with significant upper limb motor deficits 2-13 months after ischaemic stroke. 20 million cells 
were implanted by stereotaxic injection to the putamen ipsilateral to the cerebral infarct. The 
primary outcome was improvement by 2 or more points on the Action Research Arm Test (ARAT) 
sub-test 2 at 3 months after implantation.  
Findings: 23 patients underwent cell implantation at 8 UK hospitals a median of 7 months after 
stroke. One of 23 participants improved by the pre-specified ARAT sub-test level at 3 months, and 3 
participants at 6 and 12 months. Improvement in ARAT was seen only in those with residual upper 
limb movement at baseline. Transient procedural adverse effects were seen, but no cell-related 
adverse events occurred up to 12 months of follow-up. Two deaths were unrelated to trial 
procedures. 
Interpretation: Administration of human neural stem cells by intracerebral implantation is feasible in 
a multicentre study. Improvements in upper limb function occurred at 3, 6 and 12 months, but not in 
those with absent upper limb movement at baseline, suggesting a possible target population for 
future controlled trials. 
Funding: ReNeuron Ltd., Innovate UK (application no 32074-222145) 
Trial Registration: EudraCT Number: 2012-003482-18 
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Background: 
Stroke is the second most common cause of death and the primary cause of long-term adult 
disability.1 Cell therapies may modify early brain injury, or may enhance subsequent recovery from 
stroke through mechanisms that include modulation of inflammation, neural plasticity and 
neovascularisation via secretion of cytokines, growth and other factors in response to injury.2 Prior 
clinical studies have explored safety and feasibility of stem cell administration in either early 
subacute or chronic stages. Intravenous or intra-arterial administration of bone marrow or 
peripheral blood-derived cells of various kinds have been delivered predominantly in the subacute 
phase days to weeks after stroke, intended to modulate early secondary brain injury through 
systemic action. This has been explored in several small feasibility studies3-8 and in two completed 
randomised trials of insufficient size to reliably determine efficacy.9,10 In chronic stroke, intracerebral 
delivery of allogeneic cells of various types has been explored.11-13 
The human neural stem cell line CTX0E03 modifies the local inflammatory response, and in animal 
models promotes both host cell neurogenesis after stroke, and host cell angiogenesis after limb 
ischaemia.14,15 CTX0E03 cells injected 4 weeks after middle cerebral artery occlusion in rats showed a 
dose-11 and implantation site-16 dependent improvement in behavioural outcome along with 
histological evidence of increased host striatal angiogenesis13 and neurogenesis.14 Pre-clinical 
observations suggest that implanted CTX0E03 cells enhance tissue repair in vivo.14,15,17  
In a Phase I safety trial, 11 patients with stable, moderate to severe functional neurological 
impairments after ischaemic stroke, underwent intracerebral implantation of CTX0E03 cells an 
average of 30 months after stroke in doses of up to 20 million cells.11 No cell-related safety issues 
were observed up to 24 months post-implantation, and modest neurological and functional 
improvements were observed in some patients. Continuing follow-up has identified no cell-related 
safety issues up to 8 years post-implantation.  
We undertook the current study of CTX0E03 cell implantation to explore effects on arm motor 
function during earlier stages of stroke recovery, gain further safety data, and assess practicality of 
multicentre recruitment. 
 
Methods: 
We undertook an open label, single arm, multi-centre study (EudraCT No: 2012-003482-18) to 
investigate the motor response of the weak arm following stereotaxic intra-striatal injection of 
20 million CTX0E03 cells ipsilateral to a supratentorial ischaemic stroke that had occurred between 2 
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and 13 months earlier. The study was approved by the UK National Research Ethics Service and Gene 
Therapy Advisory Committee (references 13/LO1174, GTAC161, 12/LO/1963). All participants 
provided written or witnessed informed consent. The study was overseen by an independent Data 
and Safety Monitoring Board.  
Patient Eligibility: Full inclusion and exclusion criteria are detailed in the supplementary material. We 
included male or non-pregnant female patients aged ≥40 years, with imaging-confirmed 
supratentorial ischaemic stroke, and with stable arm weakness satisfying both of the following 
criteria at time of consent: National Institutes of Health Stroke Scale (NIHSS) Motor Arm Score of 2, 3 
or 4; and a score of 0 or 1 for test 2 of the Action Research Arm Test (ARAT: grasp a 2.5 cm3 block 
and move it from the starting position to the target end position).  
Main exclusion criteria were prior disabling stroke; history of intracranial haemorrhage; other 
significant functional impairment of the affected arm; contraindications to magnetic resonance 
imaging (MRI); life expectancy < 12 months; malignancy (except for non-melanoma skin cancer) 
within the previous 5 years; malignant brain tumours or metastases; current tamoxifen treatment; 
intermittent oral anti-spasticity medication.  
Sample Size: A minimum sample size of 21 treated patients was estimated to ensure that a response 
rate of ≥20% could not be excluded at the lower one-sided 50% confidence interval for the 
population mean using the Clopper-Pearson method. The desired minimum response rate was 20% 
(5/21 subjects) achieving improvement of ≥2 points on ARAT test item 2, for which the probability of 
spontaneous improvement was predicted to be <5%.  
Outcome measures: The primary outcome was the response (improvement by ≥2 points 3 months 
after cell implantation) on ARAT item 2. Secondary efficacy outcomes were numbers of participants 
showing a pre-defined minimum response on total ARAT score (≥6 points); NIHSS score (≥10 points); 
Barthel Index (≥9 points); Fugl-Meyer motor score (≥10 points on either Motor Function Upper 
Extremity score or Motor Function Lower Extremity score (added in protocol amendment 8); and 
modified Rankin Scale (mRS, ≥ 1 grade).  
Data were analysed for the overall dataset. Post-hoc subgroup analysis was undertaken for primary 
and secondary efficacy measures in patients grouped by baseline upper limb function defined by 
NIHSS arm motor score (4 versus 3 or 2).  
The Study Schedule is detailed in Supplemental Table 1. Pre-treatment assessments occurred from 
day 28 (±7 days) following the stroke up to 1- 14 days prior to implantation of CTX0E03 DP (day 0). 
Functional outcomes were evaluated 30, 90, 180 and 360 days after treatment.  
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Antiplatelet or anticoagulant treatment was withheld for a maximum of 7 days prior to surgery but 
stroke treatments as determined by the treating clinician otherwise continued throughout. All 
patients received a minimum 1.5 hours/week physiotherapy directed at the weak arm for 6 weeks. 
Additional physical and other therapy inputs were delivered according to individual patient needs, 
determined by the local clinical team.  
CTX Cells: CTX0E0318 is clonally derived from human foetal cortical neuro-epithelial cells and 
incorporates a retrovirally-inserted c-mycERTAM transgene that confers phenotypic and genotypic 
stability. CTX0E03 drug product (CTX0E03 DP) is a sterile suspension composed of CTX0E03 cells at a 
passage of ≤37 and formulated in HypoThermosol at a concentration of 5x104 cells/microL. Growth 
factors and 4-Hydroxytamoxifen (4-OHT) used in the manufacturing process are not part of the final 
formulation. Myc - dependent cell replication is curtailed by removing 4-OHT in cultures, restoring 
the cells’ capability to differentiate.19 Cryopreserved CTX0E03 DP has a shelf life of 6 months at -
135C and was thawed rapidly at the time of use. 
Procedures:  
Under general anaesthesia, a neurosurgeon experienced in stereotaxic surgery injected a single 
intracerebral dose of 20 million CTX cells (400 microL CTX0E03 DP) into the putamen ipsilateral to 
the ischaemic stroke using coordinates and trajectories based on individual pre-operative imaging, 
as previously described.11,20 CTX cells were delivered in 20 microL deposits at a rate of 5 microL /min, 
pausing for at least 20 seconds between each bolus. The deepest implant was delivered first and the 
cannula withdrawn for subsequent boluses along any single trajectory. Five deposits of 20microL 
each were placed along each of four needle tracts. Administration of the entire dose was completed 
within three hours of CTX0E03 DP being brought to room temperature. 
Protocol Evolution: The protocol and amendment history are included as supplementary material. 
The initial eligibility criteria required an NIHSS arm score of 2 or 3: this was later amended to include 
NIHSS arm score of 4 (no movement. The primary endpoint was modified to day 90 from day 180 
(amendment 8). Eligibility criteria were modified during the course of the study to remove an upper 
age limit. The Fugl-Meyer Assessment (FMA) was added to the protocol and was therefore not 
conducted in all trial participants. A Statistical Analysis Plan was finalised and approved prior to 
database lock. 
 
Role of the funding source: ReNeuron Ltd funded the study and designed the protocol with input 
from investigators. An independent contract research organisation managed data collection. 
Analysis was undertaken by an independent statistician contracted to provide the study report. The 
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funder was not aware of outcomes until database lock. The corresponding author had full access to 
all study data and had final responsibility for submission for publication. 
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Results: 
Patients were enrolled and treated between July 2014 and August 2016, and follow-up completed in 
August 2017. Of 41 patients who underwent screening for eligibility, 23 proceeded to cell injection 
(Figure 1). One patient died before 12 month follow-up (sepsis of unknown cause on day 241), and 
two others did not attend for 12 month review. Demographics, medical history and baseline stroke 
characteristics are described in Table 1. Baseline ARAT item 2 scores were zero in 22/23 and 1 in one 
participant. Successful implantation of CTX0E03 DP was completed in all 23 patients.  
Numbers of participants exhibiting predefined response criteria are detailed in Table 2. Individual 
patient data are detailed in supplementary material. 
Primary endpoint: At 3 months, one patient showed ≥2 point improvement on ARAT item 2. Three 
patients exhibited a response at 6 and at 12 months: one patient exhibiting a response at 6 months 
did not achieve the response at 12 months, but had increased scores for other ARAT test items 
(5cm3 and 7.5 cm3 blocks).  
Secondary Endpoints: Total ARAT score improved at the last observation in 7/23 patients, with 
individual improvements ranging between 1 and 54 points. Five (22%) patients met the response 
criterion of improvement by ≥6 points. No participant exhibited a change in total NIHSS score of 10 
or more points as defined in the statistical analysis plan therefore this is omitted from Table 2; 
however, only 4 participants had baseline NIHSS > 10. Change in Barthel Index of ≥9 points was seen 
in 8/20 participants at 12 months, but could not be evaluated in six subjects in whom baseline score 
was 95 or 100 (ceiling). Fugl-Meyer motor scores were undertaken in only 10 participants and 
improved by ≥10 points in 3. Improvement in mRS by ≥ 1 grade was seen in 7/20 participants at 12 
months (details in Table 2). 
Secondary Analyses: Responses rates in pre-specified assessments were explored with respect to 
age, time elapsed since stroke, and baseline NIHSS arm motor scores. No participant exhibited a 
response to all 4 scales at any time point; the number of participants exhibiting a response to 3, 2 or 
1 scales was 1, 4 and 8 at 3 months, 2,3 and 8 at 6 months, and 3, 3 and 8 at 12 months 
(Supplementary Figure 1). Changes in mRS grade were from grade 5 to 3 in 1 patient; from grade 4 
to grade 3 in 2 patients, both of whom returned to grade 4 at subsequent visits, and one of whom 
died before the 12 months assessment; grade 3 to grade 2 in 5 patients; and grade 2 to grade 1 in 1 
patient.  
At 6 months, 4/22 participants exhibited improvement in either ARAT sub-item 2 or total ARAT: the 
responders were significantly younger (mean 53 ±6 years versus 64±11 years, p=0.025) but had no 
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differences in time elapsed from stroke to intervention or total baseline NIHSS compared to non-
responders. At 12 months, 5/20 participants exhibited ARAT response as above, but no differences 
were seen in age, baseline NIHSS or time to intervention compared to non-responders.  
In nine participants, baseline NIHSS arm motor score was 4 (no movement); 14 participants had 
scores of 2 or 3, signifying at least some movement. Compared to patients with NIHSS arm scores of 
2 or 3, patients with no upper limb movement (NIHSS 4) at baseline were significantly older (70 ±8 
versus 57 ±9 years, p=0.002), had higher total NIHSS scores (median 7.5 [IQR 7] versus 6 [IQR 4], 
p=0.019) and lower Barthel scores (median 55 [IQR 38] versus 90 [IQR 31], p=0.003), but interval 
from stroke onset to treatment did not differ (median 8.5 [IQR 5] months versus 7 [IQR 6]). 
Responses on ARAT item 2 or total score were seen in none of those with baseline NIHSS arm score 
of 4 (Figure 2 and Supplementary Table 2). Improvement by one or more grades of the mRS at 
month 12 was seen in 6/12 (50%) patients with baseline NIHSS 2 or 3, and in 1/8 (12.5%) of those 
with baseline NIHSS arm score of 4. Individual patient data for all endpoints are detailed in 
supplementary Table 3. Responses were seen in both those with cortical and isolated subcortical 
infarcts (online Supplementary Table 4). 
Safety:  
There were 17 serious adverse events (SAEs) in 11 patients (Table 3). These included 2 deaths (sepsis 
on day 241, and completed suicide 7 days after the final study visit) considered unrelated to study 
procedures. Six SAEs in 4 patients were considered related to the surgical procedure, all of which 
resolved. These were: cerebral infarction identified on day 1 post-procedure, in a patient with 
carotid artery stenosis who had required prolonged general anaesthesia; subdural haemorrhage 
identified on day 2 post-procedure; headache and vomiting (days 2 – 4 post procedure); and partial 
seizures and sepsis in one participant (day 22 post-procedure) considered by local investigators to be 
possibly related to CTX0E03 cells. The seizure episode was a single, 1 hour long episode of shaking, 
commencing focally in one upper limb then spreading to the opposite arm and whole body. The 
patient was conscious throughout. Onset was concurrent with sepsis. Cerebrospinal fluid screen and 
culture were both negative, and no source of infection could be confirmed.  
One patient experienced the serious event of transient, weakly detectable HLA antibody, to antigens 
which are not expressed by the CTX0E03 cell line, coincident with an intercurrent chest infection 33 
days post-procedure. Infection was considered to be the likely stimulus for a non-specific 
immunological reaction.  
Three patients experienced hypotension during surgery, and two of these also experienced 
bradycardia, one during surgery and one during the post-operative inpatient period. 
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Discussion 
This second study of intracerebral CTX0E03 human neural stem cell injection extends the initial 
clinical data in several important respects. First, the feasibility of a multicentre clinical study was 
confirmed. The development of frozen cell product was an important technical development since 
the PISCES-1 trial to enable this. Second, additional safety data at the 20 million cell dose confirm 
few potentially cell-related adverse events up to 1 year of follow-up in both male and female 
participants, and in a wider age range than previously studied. Third, the feasibility of recruitment at 
earlier time points following stroke has been established. In the previous PISCES-1 study, median 
time from stroke to cell implantation was 30 months, compared to 7.5 months in the present study. 
Finally, exploratory data on functional outcome measures indicate both that the responder rate in a 
population expected to have a low incidence of functionally useful clinical improvement was 
sufficient to justify further clinical investigation, and that response rates on measures of upper limb 
function are likely to be poor among patients with completely absent upper limb movement at 
baseline assessment a median of 7.5 months after stroke. Preliminary data exploring activities of 
daily living, general disability and motor function suggest a range of suitable clinical outcome 
measures for future research.  
The original study design sought to determine whether a sufficient proportion of patients 
experienced response of their weak arm 3 months after implantation of CTX0E03 DP to justify 
further investigation. The intent was to exclude response rates below 20% with 90% confidence at 
this 3-month timepoint. At the 3-month evaluation, only one patient met criteria for ARAT Test 2 
response, and so the primary efficacy endpoint was not met. However, additional patients 
responded at 6 and 12 months suggesting that improvement continues beyond the 3 month time 
point. Overall, 3 participants (15% of those who completed 12 month follow-up) achieved an 
increase of at least 2 points at 12 months , and one further patient responded at 6 months but not at 
12 months, although increased scores for the larger sized blocks assessed in the ARAT. Given the 
arbitrary selection of 3 months as a time point for end-point evaluation, and absence of safety 
issues, further evaluation of CTX0E03 DP in randomised clinical trials is justified. 
Most stroke patients experience some functional recovery in the first six months post-stroke,21-23 
varying with severity of the initial deficit.24 Patients who improve early have more favourable 
functional outcome regardless of clinical syndrome, while patients who fail to show significant 
recovery by day 10 retain significant disability at day 90.25 Prediction models adjusted for the effects 
of time after stroke onset suggest that outcome is largely defined within the first weeks post-
stroke.26 Clinical predictors of dexterity at 6 months are severity of initial arm weakness, and arm 
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motor recovery in the first month after stroke, with no further improvement in prediction accuracy 
beyond this time.26-29 PISCES-2 participants were selected on the basis of poor predicted recovery, 
yet showed functionally relevant improvement in motor functions. Observations from the current 
study as well as the previous PISCES-1 study, indicate potential worthwhile functional improvements 
even with intervention occurring in the late subacute or chronic stages after stroke. 
The functional improvements observed in the study population are unlikely to have arisen as a 
consequence of additional physical therapy at the dose delivered, since very much larger doses 
appear to be necessary for an effect in chronic stroke.30,31 The possibility that lower doses of physical 
therapy interact with stem cell administration could not be excluded, however. We did not 
specifically assess other potential confounders that may lead to falsely low motor performance such 
as pain or perceptual deficits, therefore cannot completely exclude the possibility that other factors 
may have been relevant in the observed improvement. 
Expert consensus statements on trial reporting standards,32 measurement,33 and biomarkers34 were 
produced after the initiation of PISCES-2, but the trial conformed with many of these 
recommendations, including the use of NIHSS to characterise stroke severity, ARAT as a measure of 
upper limb function and the mRS as a measure of global disability. The trial framework proposed did 
not make recommendations regarding stroke recovery studies where the intervention commenced 
only in the chronic stage of stroke, however. 
Observations in PISCES-2 inform some aspects of future trial design. The ARAT response observed in 
PISCES-2 was related to the baseline degree of arm motor impairment, with no ARAT responders 
among those with absence of movement (NIHSS motor arm score of 4) at baseline. Improvements in 
mRS were also rarely observed in participants with absent arm movement at study entry. The 
Barthel index has notable ceiling effects that limit its utility, and in keeping with this, 6 participants 
could not achieve a response since already scoring near-maximum or maximum scores at baseline.35 
Consensus recommendations on appropriate outcome measures from the Stroke Recovery and 
Rehabilitation Roundtable group33 include the ARAT for upper limb function. Previous exploratory 
work on sample size requirements for motor recovery trials36 assuming a defined minimum clinically 
important difference (MCID) on ARAT of 6 points was based on a small sample size and early 
characterisation of patients: it is unclear whether the assumed MCID or changes over time apply in 
later subacute or chronic stages after stroke. Additional work to characterise predictors of motor 
response at later time points post-stroke would be beneficial in stratifying patients for future trials, 
particularly where an invasive therapy is involved. Motor response prediction algorithms developed 
for early post-stroke use, which include clinical evaluation supplemented where necessary by 
transcranial magnetic stimulation to determine the integrity of corticospinal tracts supplying upper 
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limb muscles,37 may not be applicable to later time points and require validation.34 For confirmation 
of clinically important functional outcome changes in stroke, the modified Rankin Scale has been 
favoured by regulatory bodies, and our observations support this approach. 
There are a number of limitations to this study. The open-label design was adopted due to the early 
stage of clinical investigation but may bias functional assessments. Future evaluation in a 
randomised, controlled trial is essential. Small numbers of participants inevitably mean that the 
heterogeneity of stroke cannot be adequately represented, and means that any interpretation of 
factors related to functional or neurological response must be extremely cautious. Factors such as 
age, medical comorbidities, infarct volume and location, anatomical and functional involvement of 
the corticospinal tract, time elapsed since the stroke, the anatomical location and distribution of cell 
deposits, concomitant physical therapy and its intensity, may all contribute significantly to motor 
and general recovery, and a much larger study would be required to evaluate these. While we 
observed a low incidence of potentially cell-related adverse events, the total number of patients 
implanted is small (23 in the current study and 2 at this dose level in PISCES-1) and follow-up period 
limited. 
In conclusion, PISCES-2 provides additional data to support multicentre clinical trials of intracerebral 
stem cell injection in subacute stages of stroke recovery. Functionally relevant improvement in arm 
movement was observed in patients with residual upper limb motor function at baseline. Further 
clinical investigation in a randomised, controlled clinical trial is warranted.  
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Figures and Tables: 
Figure 1: Patient disposition through the study. 
Figure 2: Median total ARAT score subdivided by baseline NIHSS upper limb motor score. Solid 
horizontal lines represent median, boxes interquartile range, error bars maximum and minimum 
values. 
Table 1: Demographics, medical history and stroke characteristics of participants. 
Table 2: Responders to Primary and Secondary Endpoints. 
Table 3: Serious adverse events occurring after surgery during the study period. 
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Table 1: Demographics, medical history and stroke characteristics of participants. 
Age (years)  Mean (SD), range 62.4 (10.8), 41 to 79 
Sex   
Male: Female  n(%) 13 (57%): 10 (43%) 
Race   
White/Caucasian n (%) 22 (96%) 
Asian n (%) 1 (4%) 
Medical History   
Hypertension  n (%) 12 (52%) 
Atrial Fibrillation  n (%) 5 (22%) 
Previous Stroke  n (%) 5 (22%) 
Ischaemic Heart Disease  n (%) 3 (13%) 
Current or Previous Smoker  n (%) 16 (70%) 
Diabetes  n (%) 2 (9%) 
Peripheral Vascular Disease  n (%) 2 (9%) 
Smoking Status   
Never smoked n (%) 7 (30%) 
Previous smoker n (%) 13 (57%) 
Current smoker n (%) 3 (13%) 
Stroke Characteristics   
Onset to Enrolment months Median (IQR), range 7 (IQR 5), range 2-13 
Affected hemisphere n (%) Left 9 (39%); Right 14 (61%) 
Location of Infarct   
Cortical n (%) 12 (52%) 
Subcortical n (%) 12 (52%) 
Basal Ganglia n (%) 8 (35%) 
Internal Capsule n (%) 7 (30%) 
Corona Radiata n (%) 5 (22%) 
Other n (%) 2 (9%) 
Both cortical and Subcortical n (%) 7 (30%) 
   
OCSP Classification   
TACS  n (%) 10 (43.48) 
PACS n (%) 8 (34.78) 
LACS n (%) 5 (21.74) 
   
NIHSS  median (range) 6 (3-15) 
UL=2 n (%) 9 (39%) 
UL=3 n (%) 5 (22%) 
UL=4 n (%) 9 (39%) 
Barthel Index median (range) 70 (15-100) 
Modified Rankin Scale (mRS) median (range) 3 (2-5) 
mRS 2 n (%) 3 (13%) 
mRS 3 n (%) 11 48%) 
mRS 4 n (%) 8 (35%) 
mRS 5 n (%) 1 (4%) 
Fugl-Meyer Assessment (n=8) Median (range)  
Upper limb  6 (2 – 22) 
Lower Limb Median (range) 18.5 (2 - 28) 
14 
 
Total motor score Median (range) 31.5 (4 - 47) 
Action Research Arm Test   
Total Score, affected arm Median (range) 0 (0 – 7) 
   
 
OCSP signifies Oxfordshire Community Stroke Project; TACS, Total Anterior Circulation Stroke; PACS, 
Partial Anterior Circulation Stroke; LACS, Lacunar Stroke; NIHSS, National Institutes of Health Stroke 
Scale; mRS, modified Rankin Scale; UL, upper limb.
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Table 2: Responders to Primary and Secondary Endpoints. 
 ARAT subtest 
2 (grasp) 
Primary 
Outcome 
ARAT Total 
Response 
Modified 
Rankin Scale 
Barthel Index 
 
FMA One or 
More 
of 
ARAT, 
mRS or 
BI 
Response 
definition 
≥2 point 
improvement 
>6 point 
improvement 
> 1 category 
improvement 
> 9 point 
improvement* 
> 10 point 
improvement
** 
 
3 months 1/23 (4%) 3/23 (13%) 7/23 (30%) 8/23 (35%) 4/10 (40%) 13/23 
(57%) 
6 months 3/22 (14%) 4/22 (18%) 6/22 (27%) 7/22 (32%)  13/22 
(59%) 
12 
months 
3/20 (15%) 5/20 (25%) 7/20 (35%) 8/20 (40%) 3/10 (30%) 14/20 
(70%) 
ARAT signifies Action Research Arm Test; mRS, modified Rankin Scale; BI, Barthel Index; FMA, Fugl-
Meyer Assessment. 
*Improvement by the specified threshold could not be evaluated in 3 subjects in whom baseline 
score was 100 and 3 subjects in whom baseline score was 95. 
**Response on Fugl-Meyer Assessment is ≥10 points on either Motor Function Upper Extremity 
score or Motor Function Lower Extremity score.
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Table 3: Serious adverse events occurring after surgery during the study period. 
System (n subjects) Event n Events Timing of SAE start 
(Days post-
procedure) 
Infections (n=5) Sepsis 2 22, 241 
 Gastroenteritis 1 108  
 Lower Respiratory Tract 
Infection 
1 2  
 Urinary Tract Infection 1 118  
 Viral infection 1 234  
Central Nervous 
System (n=5) 
Headache 2 214, 1  
 Carotid stenosis 1 0  
 Hypertonia 1 1  
 Ischaemic Stroke 1 1  
 Partial seizure 1 22  
Gastrointestinal (n=1) Vomiting 1 2  
Procedural (n=1) Subdural haemorrhage 1 25  
Immunological (n=1) HLA Positivity 1 33  
Psychiatric (n=1) Suicide 1 342  
Respiratory (n=1) Aspiration pneumonia 1 120 
 
HLA signifies human leucocyte antigen.
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Figure 1: Patient disposition through the study. 
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Figure 2: Median total ARAT score subdivided by baseline NIHSS upper limb motor score. Solid 
horizontal lines represent median, boxes interquartile range, error bars maximum and minimum 
values. 
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